MERCHANT BIOTECH FUND
Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech...
Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech...
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy...
Cancer is one of the significant causes of death worldwide. As per the World Health...
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a...
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.